Related Experiment Video

Updated: Apr 22, 2026

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection
10:15

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Published on: November 10, 2021

1.8K

Targeting CTGF, EGF and PDGF pathways to prevent progression of kidney disease

Helena M Kok1, Lucas L Falke1, Roel Goldschmeding1

  • 1Department of Pathology, H04.312, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, Netherlands.

Nature Reviews. Nephrology
|October 15, 2014
PubMed

Insights

Chronic kidney disease (CKD) involves harmful fibrotic development. This review explores TGF-β-independent pathways, like growth factors, as novel targets for antifibrotic therapies to combat kidney fibrosis.

Area of Science:

  • Nephrology
  • Fibrosis research
  • Molecular biology

Background:

  • Chronic kidney disease (CKD) presents a significant global health and economic challenge, characterized by progressive kidney fibrosis.
  • Fibrosis in CKD results from sustained release of pro-inflammatory and pro-fibrotic factors, leading to extracellular matrix accumulation.
  • While renin-angiotensin-aldosterone system blockade is standard, it fails to halt CKD progression, highlighting the need for new therapeutic strategies.

Purpose of the Study:

  • To review the roles of TGF-β-independent profibrotic pathways in CKD progression.
  • To examine the interactions between these pathways and their potential as therapeutic targets.
  • To discuss preclinical evidence supporting novel antifibrotic therapies.

Main Methods:

  • Literature review of scientific articles and preclinical studies.
  • Analysis of the molecular mechanisms of TGF-β-dependent and -independent fibrotic pathways.
  • Evaluation of growth factors and their receptors implicated in kidney fibrosis.

Main Results:

  • Transforming growth factor β (TGF-β) and angiotensin II are key drivers of kidney fibrosis.
  • TGF-β-independent pathways, including connective tissue growth factor, epidermal growth factor, and platelet-derived growth factor, significantly contribute to fibrosis.
  • These pathways represent promising targets for developing novel antifibrotic treatments.

Conclusions:

  • Targeting TGF-β-independent profibrotic pathways offers a promising strategy for novel antifibrotic therapies in CKD.
  • Further preclinical investigation is warranted to validate these pathways for therapeutic intervention.
  • Addressing multiple fibrotic mechanisms may be crucial for effectively managing CKD progression.

More Related Videos

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

1.7K
Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium08:46

Implementing Patch Clamp and Live Fluorescence Microscopy to Monitor Functional Properties of Freshly Isolated PKD Epithelium

Published on: September 1, 2015

9.2K

Related Concept Videos

Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
670
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
1.3K
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
547
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration...
4
Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
2.1K
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
1.1K